Phase 1 × Terminated × Squamous Cell Carcinoma of Head and Neck × Clear all A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
21 enrolled
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Phase 1 Terminated
30 enrolled
PEACH
Phase 1 Terminated
3 enrolled 12 charts
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Phase 1 Terminated
27 enrolled
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Phase 1 Terminated
122 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
57 enrolled
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
227 enrolled
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Phase 1 Terminated
19 enrolled
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Phase 1 Terminated
20 enrolled
STARLING
Phase 1 Terminated
31 enrolled
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
Phase 1 Terminated
38 enrolled
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
Phase 1 Terminated
5 enrolled 11 charts
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
Phase 1 Terminated
4 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Phase 1 Terminated
64 enrolled
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
119 enrolled
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Phase 1 Terminated
21 enrolled
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Phase 1 Terminated
35 enrolled
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Phase 1 Terminated
24 enrolled 29 charts
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Phase 1 Terminated
13 enrolled
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Phase 1 Terminated
14 enrolled 20 charts
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Phase 1 Terminated
66 enrolled
Safety Study of SEA-CD40 in Cancer Patients
Phase 1 Terminated
159 enrolled
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase 1 Terminated
41 enrolled 24 charts
Safety Study of AMG 228 to Treat Solid Tumors
Phase 1 Terminated
30 enrolled
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Phase 1 Terminated
49 enrolled
ILIAD
Phase 1 Terminated
21 enrolled
Safety Study of MGD009 in B7-H3-expressing Tumors
Phase 1 Terminated
67 enrolled
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase 1 Terminated
11 enrolled
A Study of LY3435151 in Participants With Solid Tumors
Phase 1 Terminated
2 enrolled 8 charts
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 1 Terminated
3 enrolled
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Phase 1 Terminated
16 enrolled
HYDRA
Phase 1 Terminated
15 enrolled
CETLEE011
Phase 1 Terminated
21 enrolled
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Phase 1 Terminated
18 enrolled
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Phase 1 Terminated
47 enrolled
Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Phase 1 Terminated
1 enrolled
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Phase 1 Terminated
13 enrolled
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Phase 1 Terminated
8 enrolled
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Phase 1 Terminated
46 enrolled
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 1 Terminated
1 enrolled